CRISM Therapeutics Completes £800,000 Placing
Why we think this is neutral
The RNS announcement indicates a completion of a placing to raise £800,000, which is a routine corporate action. There are no significant positive or negative factors that would warrant a strong sentiment score in either direction.
Key Points
- Placing to raise £800,000 (before expenses)
- Issue of 6,666,668 new ordinary shares at 12 pence per share
- Net proceeds to fund ChemoSeed clinical development
- CEO and non-executive director participated in the placing
Summary
The biotechnology company has successfully completed a £800,000 placing to fund the development of its lead product, ChemoSeed.
CRISM Therapeutics Corporation has raised £800,000 (before expenses) through a placing of 6,666,668 new ordinary shares at 12 pence per share. The net proceeds will be used to fund the GMP manufacture, sterilization, batch qualification, packaging and distribution of a clinical batch of ChemoSeed for evaluation in a Phase 2 trial, as well as clinical trial set-up costs. The company's CEO and a non-executive director participated in the placing.
Key Dates
Early 2026
First patients dosed in Phase 2 clinical trial
PLACING